Q3 2024 13F Holders as of 9/30/2024
-
Type / Class
-
Equity / Common Stock, par value $0.01 per share
-
Shares outstanding
-
27.9M
-
Number of holders
-
109
-
Total 13F shares, excl. options
-
21.2M
-
Shares change
-
-996K
-
Total reported value, excl. options
-
$220M
-
Value change
-
-$10.7M
-
Put/Call ratio
-
0.96
-
Number of buys
-
53
-
Number of sells
-
-38
-
Price
-
$10.36
Significant Holders of ENANTA PHARMACEUTICALS INC - Common Stock, par value $0.01 per share (ENTA) as of Q3 2024
118 filings reported holding ENTA - ENANTA PHARMACEUTICALS INC - Common Stock, par value $0.01 per share as of Q3 2024.
ENANTA PHARMACEUTICALS INC - Common Stock, par value $0.01 per share (ENTA) has 109 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 21.2M shares
of 27.9M outstanding shares and own 76.08% of the company stock.
Largest 10 shareholders include FARALLON CAPITAL MANAGEMENT LLC (2.11M shares), VANGUARD GROUP INC (1.98M shares), BlackRock, Inc. (1.9M shares), Krensavage Asset Management, LLC (1.5M shares), MORGAN STANLEY (1.1M shares), ARMISTICE CAPITAL, LLC (1M shares), MARSHALL WACE, LLP (851K shares), ACADIAN ASSET MANAGEMENT LLC (849K shares), Soleus Capital Management, L.P. (786K shares), and MILLENNIUM MANAGEMENT LLC (731K shares).
This table shows the top 109 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.